Quarterly ResultAug 11, 2026, 08:36 AM
Imunon Reports Q2 Net Loss $2.81M; Substantial Doubt on Going Concern
AI Summary
Imunon, Inc. reported a net loss of $2.81 million for the second quarter and $7.06 million for the six months ended June 30, 2026. The company disclosed substantial doubt about its ability to continue as a going concern due to recurring operating losses and significant cash burn. To address funding needs, Imunon raised capital through the issuance of preferred stock and notes payable, totaling over $9 million in financing activities during the six-month period.
Key Highlights
- Substantial doubt raised about Imunon's ability to continue as a going concern.
- Net loss for Q2 2026 was $2.81 million, compared to $2.74 million in Q2 2025.
- Net loss for H1 2026 was $7.06 million, up from $6.84 million in H1 2025.
- Net cash used in operating activities for H1 2026 increased to $7.01 million.
- Financing activities provided $10.16 million in H1 2026, including $7.03 million from notes payable.
- Cash and cash equivalents decreased to $6.86 million as of June 30, 2026, from $8.78 million at year-end 2025.
- Total liabilities increased to $10.80 million from $5.23 million at December 31, 2025.
- Basic and diluted net loss per share improved to $(1.38) for H1 2026 from $(6.08) for H1 2025.
Price Impact
More from IMNN